These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 26575167

  • 1. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, Zhang G, Li J, Yan B, Tang HW, Li SS, Wang LD, Zhang SJ.
    Oncotarget; 2016 Jan 19; 7(3):2462-74. PubMed ID: 26575167
    [Abstract] [Full Text] [Related]

  • 2. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T, Bai JY, She C, Yu DJ, Zhou XZ, Zhao TL.
    Cell Signal; 2018 Jan 19; 42():106-113. PubMed ID: 29050985
    [Abstract] [Full Text] [Related]

  • 3. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X, Wu H, Huang P, Zhang F.
    J Oral Pathol Med; 2019 Jan 19; 48(1):43-51. PubMed ID: 30269363
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X, Zhu A, Gu X, Xie G.
    Cell Oncol (Dordr); 2019 Jun 19; 42(3):369-380. PubMed ID: 30788663
    [Abstract] [Full Text] [Related]

  • 7. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH, Eun JW, Choi SK, Shen Q, Choi WS, Han JW, Nam SW, You JS.
    Oncotarget; 2016 May 31; 7(22):32628-40. PubMed ID: 27081696
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y, Wang L, Du Y, Liu X, Chen Z, Weng X, Guo J, Chen H, Wang M, Wang X.
    Int J Oncol; 2018 Dec 31; 53(6):2503-2517. PubMed ID: 30272279
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
    Wang L, Wu X, Huang P, Lv Z, Qi Y, Wei X, Yang P, Zhang F.
    Oncol Rep; 2016 Oct 31; 36(4):1989-96. PubMed ID: 27573714
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y, Sun M, Zhan X, Wu C, Geng P, Sun X, Wu Y, Zhang S, Qin J, Zhuang Z, Liu Y.
    J Exp Clin Cancer Res; 2019 Feb 15; 38(1):83. PubMed ID: 30770740
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW.
    Carcinogenesis; 2014 Dec 15; 35(12):2807-14. PubMed ID: 25322871
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E, Croci O, Sabò A, Muller H, Morelli MJ, Pelizzola M, Campaner S.
    Leukemia; 2017 Feb 15; 31(2):479-490. PubMed ID: 27443262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.